Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paxman ABPXMBF 81 Equity-to-Asset is 0.86 as of Mar. 2026, which is 23% above its 10-year median of 0.70. GuruFocus rates PXMBF with a GF Score™ of 81/100 and a GF Value™ of $4.70. The stock has 3 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Paxman AB ranks better than 85.33% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Paxman AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $43.85 Mil. Paxman AB's Total Assets for the quarter that ended in Mar. 2026 was $51.00 Mil.
Therefore, Paxman AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.86.
The historical rank and industry rank for Paxman AB's Equity-to-Asset or its related term are showing as below:
PXMBF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14 Med: 0.7 Max: 0.98
Current: 0.86
During the past 9 years, the highest Equity to Asset Ratio of Paxman AB was 0.98. The lowest was 0.14. And the median was 0.70.
PXMBF's Equity-to-Asset is ranked better than 85.33% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs PXMBF: 0.86
Paxman AB (OTCPK:PXMBF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Paxman AB Equity-to-Asset Related Terms
Paxman AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Paxman AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PXMBF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Paxman AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paxman AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Paxman AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Paxman AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paxman AB (PXMBF) has a Equity-to-Asset of 0.86 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Paxman AB and its competitors. This is 23% above median its historical median of 0.70. Over the past decade, Paxman AB's Equity-to-Asset has ranged from 0.14 to 0.98. According to the industry distribution chart, Paxman AB ranks #125 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 14.7%.
Is Paxman AB's Equity-to-Asset too high?
Paxman AB's current Equity-to-Asset of 0.86 is 23% above median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.98. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Paxman AB's value of 0.86 is 34.4% above this industry median. Based on the distribution chart, Paxman AB ranks #125 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Paxman AB has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Paxman AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Paxman AB ranks #125 out of 852 companies for Equity-to-Asset. This places Paxman AB in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Paxman AB's value of 0.86 is 34.4% above this benchmark. Historically, Paxman AB's own Equity-to-Asset has ranged from 0.14 to 0.98 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.64, Paxman AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paxman AB's current Equity-to-Asset of 0.86 is 34.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Paxman AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paxman AB's current Equity-to-Asset is 0.86, which is 23% above median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paxman AB stock overvalued right now?
Paxman AB (PXMBF) has a current Equity-to-Asset of 0.86. The stock's GF Value™ is $4.70, compared to a current price of $3.50 — trading 25.5% below its estimated fair value. The current Equity-to-Asset is 0.86, which is 23% above median its 10-year median of 0.70 and 34.4% above the Medical Devices & Instruments industry median of 0.64. Paxman AB's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Paxman AB (PXMBF), the current Equity-to-Asset is 0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paxman AB (PXMBF) Overvalued in 2026?
Based on GuruFocus' analysis, Paxman AB stock appears to be undervalued.
The current stock price of $3.50 is trading 25.5% below its estimated GF Value™ of $4.70.
Key valuation signals for PXMBF:
Equity-to-Asset: 0.86 (23% above median its 10-year median of 0.70)
GF Value™: $4.70 vs. price of $3.50 (25.5% below fair value)
Industry Position: 34.4% above the Medical Devices & Instruments median (#125 of 852)
No single metric tells the full story. See the PXMBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paxman AB is a Sweden-based company engaged in the development of the PAXMAN Scalp Cooling System, which has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The portfolio includes both the Paxman and Digni Capsystems with several installations in hospitals, clinics, and treatment centres world-wide.
81GF Score
Get the complete analysis for PXMBF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PXMBF has been successfully added to your 
